

1616/11
PC8626CJTJ

TECH CENTER 1600/2900

10/01/2003 ZJHAR1 00000051 161455 09802628

RECEIVED

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 23rd day of September 2003.

By _____

(Signature of person mailing)

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

William J. Curatolo, et al.

APPLICATION NO.: 09/803,628

Examiner: R. DeWitty

FILING DATE: March 9, 2001

Group Art Unit: 1616

TITLE: Controlled-Release Dosage Forms of Azithromycin

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

The Commissioner is hereby authorized to charge the sum of \$180.00 to Deposit Account No. 16-1445 to cover the cost of this submission in accordance with 37 CFR 1.97(c) and 1.17(p). The Commissioner is further authorized to charge any additional fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment, to Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: September 23, 2003

James T. Jones
James T. Jones
Attorney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4903

4/97, M2, (1/1)

01 FC:1806 180.00 DA
10/01/2003 ZJHAR1 00000051 161455

O I P E
SEP. 26 2003
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC8626CJTJ			SERIAL NO. 09/803,628				
			APPLICANT William J. Curatolo, et al.			FILING DATE March 9, 2001				
Page 1 of 1						GROUP 1616				
U.S. PATENT DOCUMENTS										
EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS									TRANSLATION	
DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									RECEIVED	
		Fiese, et al., Jml of Antimicrobial Chemotherapy, 1990, 25, suppl. A, pgs 39-47							TECH CENTER 1600/2000	
		Anie, et al., Intrnl Jml of Pharmaceutics, 76, 1991, pgs 183-185							OCT 02 2003	
		Khosla, et al., Intrnl Jml of Pharmaceutics, 62, 1990, pgs R9-R11								
		Knutson, et al., The Am Jml of Gastroenterology, 1989, vol. 84, no. 10, pgs 1278-1284								
		Jobin, et al., Br. J. Clin. Pharmac, 1985, 19, pgs 97S-105S								
		Blankenhorn, Socl. Exp. Biol. Med, 1955, 88, pgs 356-362								
		Graffner, et al., Pharm Research, vol. 7, no. 1, 1990, pgs 54-58								
		Fischer, et al., Pharm Research, vol. 4, no. 6, 1987, pgs 480-485								
		Welling, P., 1986, ACS Monograph 185, American Chemical Society, pp. 173-178								
		Langenbucher, et al., Br. J. Clin. Pharmac, 1985, 19, pgs 151S-162S								
EXAMINER			DATE CONSIDERED							
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>										